Tumor Mutational Burden and
Adult
Aged
B7-H1 Antigen
/ antagonists & inhibitors
Biomarkers, Tumor
/ genetics
Cohort Studies
Female
Follow-Up Studies
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Immunotherapy
/ methods
Middle Aged
Mutation
PTEN Phosphohydrolase
/ genetics
Prognosis
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Survival Rate
Triple Negative Breast Neoplasms
/ drug therapy
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
received:
30
10
2019
revised:
20
12
2019
accepted:
30
01
2020
pubmed:
6
2
2020
medline:
4
9
2021
entrez:
6
2
2020
Statut:
ppublish
Résumé
Few patients with metastatic triple-negative breast cancer (mTNBC) benefit from immune checkpoint inhibitors (ICI). On the basis of immunotherapy response correlates in other cancers, we evaluated whether high tumor mutational burden (TMB) ≥10 nonsynonymous mutations/megabase and We identified patients with mTNBC, who consented to targeted DNA sequencing and were treated with ICIs on clinical trials between April 2014 and January 2019 at Dana-Farber Cancer Institute (Boston, MA). Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were correlated with tumor genomic features. Sixty-two women received anti-PD-1/L1 inhibitors alone (23%) or combined with targeted therapy (19%) or chemotherapy (58%). High TMB (18%) was associated with significantly longer PFS (12.5 vs. 3.7 months; Among patients with mTNBC treated with anti-PD-1/L1 therapies, high TMB and
Identifiants
pubmed: 32019858
pii: 1078-0432.CCR-19-3507
doi: 10.1158/1078-0432.CCR-19-3507
pmc: PMC7269810
mid: NIHMS1557408
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Immune Checkpoint Inhibitors
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2565-2572Subventions
Organisme : NCI NIH HHS
ID : P50 CA168504
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Cancer Discov. 2019 Feb;9(2):176-198
pubmed: 30679171
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Ann Oncol. 2019 Mar 1;30(3):397-404
pubmed: 30475950
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
JCI Insight. 2016 Nov 17;1(19):e87062
pubmed: 27882345
Breast Cancer Res Treat. 2017 Aug;164(3):627-638
pubmed: 28500398
Cell Rep. 2016 Oct 18;17(4):1206
pubmed: 27760322
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
J Exp Med. 2016 Dec 12;213(13):2835-2840
pubmed: 27903604
Arch Pathol Lab Med. 2017 Jun;141(6):751-758
pubmed: 28557599
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
JCI Insight. 2018 Feb 22;3(4):
pubmed: 29467336
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
Oncotarget. 2015 Oct 27;6(33):34221-7
pubmed: 26439694
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nature. 2012 Feb 08;482(7385):405-9
pubmed: 22318517
BMC Cancer. 2015 Dec 16;15:963
pubmed: 26672755
Breast Cancer Res Treat. 2018 Feb;167(3):671-686
pubmed: 29063313
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Nature. 2015 Apr 30;520(7549):692-6
pubmed: 25901682
Immunity. 2017 Feb 21;46(2):197-204
pubmed: 28228279
Cell. 2017 Nov 16;171(5):1042-1056.e10
pubmed: 29056344
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Ann Oncol. 2020 Mar;31(3):387-394
pubmed: 32067680
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254